Innovations in Percutaneous Intervention, 1977-2007. Slides created by Simon H. Stertzer, MD, FACC, FAHA, Professor Emeritus, Stanford University School of Medicine.
Coronary Balloon Angioplasty and Stents Procedure Information by We CareP Nagpal
Balloon Angioplasty Surgery India,Cost Balloon Angioplasty Surgery Delhi,Balloon Angioplasty Surgery Cost In India Info On Cost Balloon Angioplasty Surgery Mumbai Delhi Bangalore India,Balloon Angioplasty Surgery Center Hospitals India,Balloon Angioplasty Surgery Surgeon India,Balloon Angioplasty Surgery Doctors Mumbai India
Coronary Balloon Angioplasty and Stents Procedure Information by We CareP Nagpal
Balloon Angioplasty Surgery India,Cost Balloon Angioplasty Surgery Delhi,Balloon Angioplasty Surgery Cost In India Info On Cost Balloon Angioplasty Surgery Mumbai Delhi Bangalore India,Balloon Angioplasty Surgery Center Hospitals India,Balloon Angioplasty Surgery Surgeon India,Balloon Angioplasty Surgery Doctors Mumbai India
coronary artery bypass graft surgery CABGSunil kumar
coronary artery bypass graft surgery, explanation of CABG on-pump and off-pump procedures, physiotherapy management after surgery. indications of CABG. description of the procedure, investigations before surgery, per operative and post operative management
The heart contains 4 chambers: the right atrium, left atrium, right ventricle, and left ventricle. The atria are smaller than the ventricles and have thinner, less muscular walls than the ventricles. The ventricles are connected to the arteries that carry blood away from the heart.
Coronary artery bypass grafting (CABG) is a type of surgery that improves blood flow to the heart. It's used for people who have severe coronary heart disease (CHD), also called coronary artery disease.
Beating Heart Bypass Surgery – Things you should knowMohammad Shakil
Coronary Artery Bypass Grafting (CABG), commonly referred Bypass Surgery, is a surgical procedure that redirects blood flow around a blockage or narrowed section in the major arteries supplying blood and oxygen to the heart.
Heart valve replacement surgery procedurePeter D'Souza
Heart valve replacement surgery is a surgical procedure by which cardiac surgeons eliminate a damaged heart valve & replace it with grafts or portions from body tissues or with artificial heart valves to improve the normal functioning of the heart. https://goo.gl/gg6JsJ
Angioplasty uses imaging guidance to insert a balloon-tipped catheter into a narrow or blocked blood vessel where the balloon is inflated to open the vessel and improve blood flow. It may be done with vascular stenting – the placement of a small wire mesh tube within the blood vessel to help keep it open. The procedure is much less invasive than other surgical interventions and usually does not require general anesthesia.
Heberden meticulously described a symptom, but he did not understand the disease. Edward Jenner noticed thickened coronary arteries at autopsy of his colleague John Hunter who had died suddenly after an angina attack in 1793,2 but it took decades for a first remedy for angina pectoris and even longer for a true understanding of the underlying disease
coronary artery bypass graft surgery CABGSunil kumar
coronary artery bypass graft surgery, explanation of CABG on-pump and off-pump procedures, physiotherapy management after surgery. indications of CABG. description of the procedure, investigations before surgery, per operative and post operative management
The heart contains 4 chambers: the right atrium, left atrium, right ventricle, and left ventricle. The atria are smaller than the ventricles and have thinner, less muscular walls than the ventricles. The ventricles are connected to the arteries that carry blood away from the heart.
Coronary artery bypass grafting (CABG) is a type of surgery that improves blood flow to the heart. It's used for people who have severe coronary heart disease (CHD), also called coronary artery disease.
Beating Heart Bypass Surgery – Things you should knowMohammad Shakil
Coronary Artery Bypass Grafting (CABG), commonly referred Bypass Surgery, is a surgical procedure that redirects blood flow around a blockage or narrowed section in the major arteries supplying blood and oxygen to the heart.
Heart valve replacement surgery procedurePeter D'Souza
Heart valve replacement surgery is a surgical procedure by which cardiac surgeons eliminate a damaged heart valve & replace it with grafts or portions from body tissues or with artificial heart valves to improve the normal functioning of the heart. https://goo.gl/gg6JsJ
Angioplasty uses imaging guidance to insert a balloon-tipped catheter into a narrow or blocked blood vessel where the balloon is inflated to open the vessel and improve blood flow. It may be done with vascular stenting – the placement of a small wire mesh tube within the blood vessel to help keep it open. The procedure is much less invasive than other surgical interventions and usually does not require general anesthesia.
Heberden meticulously described a symptom, but he did not understand the disease. Edward Jenner noticed thickened coronary arteries at autopsy of his colleague John Hunter who had died suddenly after an angina attack in 1793,2 but it took decades for a first remedy for angina pectoris and even longer for a true understanding of the underlying disease
The intent of this presentation is to provide an update of coronary assessment and management for the adult intensivist. Discussion points will include:
1. An assessment of coronary severity, using established methods, in particular fractional flow reserve (FFR),
2. Which stent- highlight the evolution of the stent to the current generation and what is evolving,
3. How to keep the stent open with current concepts of antiplatelet therapy and how this impacts the critically ill patient
4. What to consider if the ECG is abnormal, but the coronaries are not flow limiting obstruction- an occasional dilemma in the critically ill patient and finally
5. Discussion around a contemporary study regarding cardiogenic shock and coronary ischemia.
TCT 2010 research highlights: A slideshow presentation theheart.org
http://www.theheart.org/editorial-program/1128553.do
The 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium took place in Washington. Key trials presented at the meeting include: PARTNER, ZILVER PTX, ISAR-TEST 4,SORT-OUT 4, COMPARE,SPIRIT IV, HORIZONS-AMI, BIOFREEDOM, PROTECT-AF, CAP and Robotically assisted PCI
Lung Cancer: Artificial Intelligence, Synergetics, Complex System Analysis, S...Oleg Kshivets
RESULTS: Overall life span (LS) was 2252.1±1742.5 days and cumulative 5-year survival (5YS) reached 73.2%, 10 years – 64.8%, 20 years – 42.5%. 513 LCP lived more than 5 years (LS=3124.6±1525.6 days), 148 LCP – more than 10 years (LS=5054.4±1504.1 days).199 LCP died because of LC (LS=562.7±374.5 days). 5YS of LCP after bi/lobectomies was significantly superior in comparison with LCP after pneumonectomies (78.1% vs.63.7%, P=0.00001 by log-rank test). AT significantly improved 5YS (66.3% vs. 34.8%) (P=0.00000 by log-rank test) only for LCP with N1-2. Cox modeling displayed that 5YS of LCP significantly depended on: phase transition (PT) early-invasive LC in terms of synergetics, PT N0—N12, cell ratio factors (ratio between cancer cells- CC and blood cells subpopulations), G1-3, histology, glucose, AT, blood cell circuit, prothrombin index, heparin tolerance, recalcification time (P=0.000-0.038). Neural networks, genetic algorithm selection and bootstrap simulation revealed relationships between 5YS and PT early-invasive LC (rank=1), PT N0—N12 (rank=2), thrombocytes/CC (3), erythrocytes/CC (4), eosinophils/CC (5), healthy cells/CC (6), lymphocytes/CC (7), segmented neutrophils/CC (8), stick neutrophils/CC (9), monocytes/CC (10); leucocytes/CC (11). Correct prediction of 5YS was 100% by neural networks computing (area under ROC curve=1.0; error=0.0).
CONCLUSIONS: 5YS of LCP after radical procedures significantly depended on: 1) PT early-invasive cancer; 2) PT N0--N12; 3) cell ratio factors; 4) blood cell circuit; 5) biochemical factors; 6) hemostasis system; 7) AT; 8) LC characteristics; 9) LC cell dynamics; 10) surgery type: lobectomy/pneumonectomy; 11) anthropometric data. Optimal diagnosis and treatment strategies for LC are: 1) screening and early detection of LC; 2) availability of experienced thoracic surgeons because of complexity of radical procedures; 3) aggressive en block surgery and adequate lymph node dissection for completeness; 4) precise prediction; 5) adjuvant chemoimmunoradiotherapy for LCP with unfavorable prognosis.
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
Ethanol (CH3CH2OH), or beverage alcohol, is a two-carbon alcohol
that is rapidly distributed in the body and brain. Ethanol alters many
neurochemical systems and has rewarding and addictive properties. It
is the oldest recreational drug and likely contributes to more morbidity,
mortality, and public health costs than all illicit drugs combined. The
5th edition of the Diagnostic and Statistical Manual of Mental Disorders
(DSM-5) integrates alcohol abuse and alcohol dependence into a single
disorder called alcohol use disorder (AUD), with mild, moderate,
and severe subclassifications (American Psychiatric Association, 2013).
In the DSM-5, all types of substance abuse and dependence have been
combined into a single substance use disorder (SUD) on a continuum
from mild to severe. A diagnosis of AUD requires that at least two of
the 11 DSM-5 behaviors be present within a 12-month period (mild
AUD: 2–3 criteria; moderate AUD: 4–5 criteria; severe AUD: 6–11 criteria).
The four main behavioral effects of AUD are impaired control over
drinking, negative social consequences, risky use, and altered physiological
effects (tolerance, withdrawal). This chapter presents an overview
of the prevalence and harmful consequences of AUD in the U.S.,
the systemic nature of the disease, neurocircuitry and stages of AUD,
comorbidities, fetal alcohol spectrum disorders, genetic risk factors, and
pharmacotherapies for AUD.
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
30 years of percutaneous coronary intervention.pptx
1. •Percutaneous Coronary Intervention 2007:
30 years
⬜ S. H. Stertzer, MD, FACC, FAHA
⬜ Professor of Medicine,
⬜ Division of Cardiovascular Medicine
⬜ Stanford University School of Medicine
⬜ Stanford, CA
2. Innovations in Percutaneous Intervention
1977-2007
• Simple balloon angioplasty 1977
• Over-the-wire advance 1979
• Monorail alternatives 1981
• Directional and Rotational atherectomy
• Retrieval atherectomy- Pathway Medical
• Bare metal stents 1987
• DES, first generation 1999; PI:Valves, etc.
• DES 2nd
generation; PI: Myocardial regeneration
therapy 2008
4. In 1929 in a small hospital in Eberswald Germany, Werner Forssmann, a
young surgical resident, anesthetized his own elbow, inserted a catheter
in his antecubital vein and, catheter dangling from his arm, proceeded to
a basement x-ray room where he documented the catheter's position in
his right atrium — proving that a catheter could be inserted safely into a
human heart
5. 1958 - While conducting an imaging procedure in which dye
was to be injected into the aortic valve of a patient with
valvular disease, Dr. Mason Sones a pediatric cardiologist at
The Cleveland Clinic discovered that the catheter had
accidentally entered the patient's right coronary artery and,
before it could be removed, 30cc's of contrast dye had been
released.
6. 1967 An associate of Dr. Charles Dotter at the University of
Oregon in Portland, radiologist Dr. Melvin Judkins studied
coronary angiography with Dr. Mason Sones; Judkins went
on to create his own system of diagnostic imaging,
introducing a series of specialized catheters and perfecting
the transfemoral approach
7. 1976 After employing Dotter's techniques of transluminal angioplasty, which he had
learned from Eberhart Zeitler in Nuremberg, Andreas Gruentzig, a young German
physician working at University Hospital in Zurich, Switzerland, began toying with
the idea of adding a balloon to the Dotter catheters. He started fashioning
prototypes in his own kitchen, searching for a viable material and design. In 1975
he developed a double-lumen catheter fitted with a polyvinylchloride balloon that
would set in motion a revolution in medicine.
35. Percutaneous Intervention
Beyond the current era:
1. Newer stent platforms-
a. stent itself
b. abolition of plastic polymer coating-
c. drug changes: e.g., cerivastatin
2. Myocardial regeneration
3. Other structural PI advances - valves,
IA occluders, L atrial exclusion, EP-
36. Today’s Drug/Polymer Paradigm
⬜ Efforts began in 2002, (e.g.,Stanford/ Medlogics)
to address issues with first generation drug
eluting stents that investigators considered
would arise when:
◼ A stent is “jacketed” in plastic; and
◼ That plastic holds and releases a toxic substance.
37. A Next Generation Stent System,
needs to be:
⬜ A superior platform for DES
⬜ Thinner Stent Struts 71 – 78um
◼ Cf. Driver = 91 um
Vision = 81 um
⬜ Lower Stent Recoil <3%
⬜ Lower Crossing Profile < 1.0mm (for all diameters
including 4.0mm)
⬜ Shift Stress Concentration Away from Crown Inner
Radius
⬜ 7, 9 Crown; 1.2mm Segment (2.50-4.0mm)
⬜ Submission for CE Mark by September 2007
40. The Drugs
⬜ Current DES drugs are typically either rapamycin
derivatives or paclitaxel.
⬜ All of these drugs delay, impede, or prevent
complete healing and/or promote endothelial
dysfunction.
74. Recent Intracoronary Delivery Autologous Bone
Marrow Stem Cell Therapy Clinical Trials
(IC)
⬜ REPAIR MI – Randomized controlled trial of 205 patients treated 3-6
days post MI showed a statistical improvement in left ventricular
ejection fraction improvement at 4 months (Schachinger: AHA, 2005)
⬜ ASTAMI – Randomized controlled trial of 100 patients treated 5-8 days
post MI showed a statistical decrease in left ventricular ejection
fraction at 6 months (Lunde: AHA, 2005)
⬜ ACUTE STEMI - Randomized controlled trial of 67 patients treated post
MI showed no statistical changes in global left ventricular ejection
fraction improvement at 4 months but a statistically significant decline
in infarct size as measured using MRI (Janssens: Lancet, 2005)
75. Poor delivery efficiencies with cells delivered IC
related to peripheral tissue losses
Only 1.3 to 2.6% 1 hour after
delivery
Hofmann, Circ.2005
76. Intramyocardial Delivery Has Superior Retention to other
Delivery Modalities
Dou, Circ. 2005
IM 12%
1 hour after
IC 2.6%
1 hour after
IRV 3.2%
1 hour after
78. HelixTM
biotherapeutic delivery catheter
• Stable delivery platform
• confirm position
• control delivery depth
• control rate of delivery
• Self sealing helical pathway
• Double barrel design to confirm
position with contrast at base of helix
• Dwell period after delivery uses
stability to prevent back leak into
ventricular chamber
79. Helical Needle Intramyocardial Delivery
⬜ BioCardia’s catheter is
advanced from an artery in the
leg of the patient and into the
large pumping chamber of the
heart called the left ventricle.
⬜ From within this very dynamic
space the helical needle is
steered with BioCardia’s
deflectable Morph catheter and
the helical needle can be
advanced and rotated into the
heart muscle to deliver
biotherapeutics.
Video of Intramyocardial Delivery of Contrast
to Provide Qualitative Understanding of Local
Pharmacokinetics and Value of Helix Stability
80. Lead Program: Stem Cells from Autologous Bone
Marrow
•9am Marrow Harvested
•10am Cells Processed
•3pm Cells Delivered
83. TABBMMI Trial Results: Increase in Ejection Fraction
is Statistically and Clinically Significant at 12 Months
84. A B
Improvement in Ejection Fraction Example
Right anterior oblique left ventriculogram on date of
procedure (A) and at 6 month follow-up (B) showing
significant ejection fraction (EF) changes.
85. Helix improves retention over straight needle (JNJ)
and other delivery modalities in studies using
radiolabelled FGF-2
IP = Intra pericardial
IC = Intracoronary
IM JNJ = Johnson and Johnson Catheter
IM BioCardia = BioCardia Catheter
86. Conclusions, 2007:
⬜ Past 30 years have seen the most remarkable
advances in PCI
⬜ New DES will hopefully arrest LST-ReS
⬜ Retrieval atherectomy may yet remove clot and
residual plaque
⬜ MR, AF and some AVR may all be treated by PCI
⬜ Myocardium may be regenerated in CHF
⬜ TEBV may be available in allografts
87. THE CORONARY VEINS
(an important frontage road)
* Dye Removal
* Delivery vehicle
* Route to the valve
90. Morph: A highly controllable single use
steerable guide and sheath platform
Morph Product is FDA cleared
via 510(k) for peripheral and
cardiac applications.
91. ➢3 million guides are sold each year with a variety of shapes.
➢Morph can take on all shapes and be customized for patient.
Morph®
Video Demo
92. Clinical experience has been stellar.
Perfect safety record >1400 typically difficult clinical cases.
115 hospital customers ordering Morph®
Carotid- AAA- Dr. Arko Lumbar – Dr. Ansel
Dr. Eles
Celiac- Dr. Frisoli Renal – Dr. Bates SMA- Dr. Das
93. Morph ®
Sheath-Guide
to capture the broader opportunity
⬜ 6F and 7F Guide Sheaths
⬜ Every guide shape that can be customized to the
patient
⬜ Sheath type back up support in a shaped catheter (only
the Morph®
can do this today)
⬜ First product inserted into patient – determinant of
what goes in next.
